Exenatide for Treating Cocaine Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

November 17, 2021

Study Completion Date

November 17, 2021

Conditions
Cocaine Use Disorder
Interventions
DRUG

Exenatide 2 mg [Bydureon]

Exenatide will be purchased commercially as Bydureon® for subcutaneous (SC) injection and administered at a dose of 2 mg once a week for a total of 6 weeks. Each single-dose, dual-chamber pen contains 0.65 mg of diluent and 2 mg of exenatide, which remains isolated until mixed.

BEHAVIORAL

Drug Counseling

Once weekly drug counseling sessions for cocaine use with trained masters-level therapists.

Trial Locations (1)

77054

UTHealth Behavioral and Biomedical Sciences Building, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER